Although the clinical features of the Isocitrate dehydrogenase 2 (IDH2) mutation in acute myeloid leukemia (AML) have been characterized, its prognostic significance remains controversial and its stability has not been investigated. We analyzed 446 adults with primary non-M3 AML and found IDH2 R172, R140 and IDH1 R132 mutations occurred at a frequency of 2.9, 9.2 and 6.1%, respectively. Compared with wild-type IDH2, mutation of IDH2 was associated with higher platelet counts, intermediate-risk or normal karyotype and isolated þ 8, but was inversely correlated with expression of HLA-DR, CD34, CD15, CD7 and CD56, and was mutually exclusive with WT1 mutation and chromosomal translocations involving core-binding factors. All these correlations became stronger when IDH1 and IDH2 mutations were considered together. Multivariate analysis revealed IDH2 mutation as an independent favorable prognostic factor. IDH2 À /FLT3-ITD þ genotype conferred especially negative impact on survival. Compared with IDH2 R140 mutation, IDH2 R172 mutation was associated with younger age, lower white blood cell count and lactate dehydrogenase level, and was mutually exclusive with NPM1 mutation. Serial analyses of IDH2 mutations at both diagnosis and relapse in 121 patients confirmed high stability of IDH2 mutations. In conclusion, IDH2 mutation is a stable marker during disease evolution and confers favorable prognosis.
Introduction
The increasing number of genetic alterations discovered in acute myeloid leukemia (AML) has not only increased our understanding of this heterogeneous disease but also provided prognostic information through which individualized treatment for the best interests of patients may become possible. These impacts of genetic mutations have been underscored by the inclusion of NPM1 and CEBPA mutations in the 2008 World Health Organization classification of AML.
Among these genetic alterations, mutations of Isocitrate dehydrogenase 1 (IDH1) and IDH2, which encode two isoforms of isocitrate dehydrogenase, are special in that these genes are involved in metabolism, 1,2 rather than signaling pathways or transcription factors, which are commonly deranged in AML.
The clinical and biological characterization of IDH mutations in myeloid malignancies have been reported in several studies. IDH mutations occur at low frequencies (3.6-5%) in myelodysplastic syndrome, 3, 4 and in chronic-phase myeloproliferative neoplasm (about 1.8%), 5, 6 but obviously increased as these diseases progress to AML (7.5-21%), [3] [4] [5] [6] indicating a role of IDH mutations in leukemogenesis. In AML, IDH2 mutations occur more frequently than IDH1 mutations, with frequencies of 11 vs 6% in patients younger than 60 years, 7 15.4 vs 7.7% in total patients, 8 and 19 vs 14% in adults with normal karyotype. 9 Although IDH1 and IDH2 proteins locate differently, in cytosol and mitochondria, respectively, they both function to generate a-ketoglutarate and are supposed to control redox status in cells. 10, 11 The IDH mutants gain the neomorphic enzyme activity and lead to the production of an onco-metabolite, 2-hydroxyglutarate (2-HG), which was speculated to upregulate hypoxia-inducing factor 1a by inhibition of prolyl hydroxylase. 1, 2, 10, 12 On the basis of the in vivo functions of IDH1 and IDH2, it is intuitive to expect similar clinical and biological characteristics between AML bearing mutations of these two genes. Indeed, mutations of both genes are more commonly present in patients with normal cytogenetics. 7, [13] [14] [15] [16] [17] However, different features between IDH1-mutated and IDH2-mutated AML were shown in several reports, and even there existed differences between IDH2 R140 and R172 mutations. 9, 17, 18 In addition, the prognostic implications of these mutations also varied widely among different institutions. 7, 15, 17 More perplexingly, IDH2 R172 mutation alone was found to have distinct gene-and microRNA-expression profiles, 9 and appeared to be an independent poor prognostic factor. 18 In contrary, results from two studies suggested a possible favorable impact of IDH2 mutation in subgroups of AML patients. 7, 8 Overall, the prognostic implication of IDH2 mutation is still controversial. Moreover, the side-by-side comparison is needed to delineate the similarities and distinctions among mutations at IDH1 R132, IDH2 R140 and IDH2 R172. Finally, the stability of IDH2 mutation remains uninvestigated.
We have previously reported the clinical and biological characteristics of AML patients with IDH1 mutation at R132. 14 To further clarify the above issues of IDH1 and IDH2 mutations in AML, we then analyzed 446 adults with non-M3 AML in our institute. We found that IDH2 mutations were associated with some distinct biological features and implicated a longer overall survival (OS) in all non-M3 patients and in those with a normal karyotype. Moreover, IDH2 mutation was an independent favorable prognostic factor in multivariate analysis. Finally, by a comprehensive sequential study, we confirmed that IDH2 mutation, like IDH1 mutation we previously described, 14, 19 was a stable mutation during disease evolution.
Materials and methods

Patients
From 1995 to 2007, a total of 674 adult patients with de novo AML were diagnosed at the National Taiwan University Hospital according to the French-American-British Cooperative Group Criteria. There were 497 patients with cryopreserved bone marrow cells and complete clinical and laboratory data for analysis. These 497 patients were representative of the whole cohort because the clinical data and treatment outcome were not different from the whole population (data not shown). Patients with AML M3 subtype were not included in the study because of their distinct treatment and prognosis. Therefore, a total of 446 adult patients (X18 years) were included in this study. Written informed consent in accordance with the Declaration of Helsinki was obtained from all participants and the study was approved by the Institutional Review Board of the National Taiwan University Hospital. The bone marrow cells were collected serially at the time of diagnosis, after chemotherapy and at relapse. Among these 446 patients, 309 patients (69.3%) received conventional induction chemotherapy (idarubicin 12 mg/m 2 per day on days 1-3 and cytarabine 100 mg/m 2 per day on days 1-7), followed by consolidation chemotherapy with 2-4 cycles of high-dose cytarabine (2000 mg/m 2 every 12 h on days 1-4, total eight doses) with or without an anthracycline (idarubicin or mitoxantrone) after achieving complete remission (CR). The remaining 137 patients received palliative therapy or low-dose chemotherapy because of poor performance status or per patients' wish. 30 and FLT3-ITD in exon 14 31 as described previously. Mutations were detected by direct sequencing on the PCR products, and the sensitivity of each assay was about 15%.
Mutation analysis
Gene cloning
When IDH2 mutations detected at diagnosis were absent in relapsed bone marrow samples by direct sequencing, we performed TA cloning (Yeastern Biotech, Taipei, Taiwan) of the PCR products spanning the mutation hotspots, followed by sequencing of individual clones to search for any mutation.
Cytogenetic analysis
Bone marrow cells were harvested directly or after 1-3 days of unstimulated culture. Metaphase chromosomes were banded by the G-banding method as described previously. 32 
Immunophenotyping
A panel of monoclonal antibodies, including myeloid-associated antigens (CD13, CD33, CD11b, CD14, CD15 and CD41a), as well as lymphoid-associated antigens (CD2, CD5, CD7, CD19, CD10 and CD20), and lineage-nonspecific antigens (HLA-DR, CD34 and CD56), was used to determine the immunophenotypes of leukemia cells as previously described. 33 
Statistics
The w 2 test was used to compare discrete variables of patients with and without gene mutation. Fisher exact test was used for comparing the incidence of IDH2 mutation between different cohorts. Mann-Whitney test method was used to compare continuous variables and medians of distributions. Only 309 patients who received conventional induction chemotherapy and subsequent consolidation chemotherapy after achieving CR were included in the survival analysis. OS was measured from the date of first diagnosis to the date of last follow-up or death from any cause. Kaplan-Meier estimation was used to plot survival curves, and log-rank tests were used to calculate the difference among groups. Patients receiving hematopoietic transplantation were censored on the day of transplantation. Multivariate Cox proportional hazard regression analysis was used to investigate independent prognostic factors for OS. A P-value o0.05 was considered statistically significant. All statistical analyses were performed using the SPSS 17 software (SPSS Inc., Chicago, IL, USA).
Results
IDH2 R140 and R172 mutations
These 446 non-APL patients consisted of 251 males and 195 females, with a median age of 53 years (range, 18-90 years). The IDH2 mutation was detected in 54 patients (12.1%), including 13 (2.9%) with R172 mutation and 41 (9.2%) with R140 mutation, whereas the IDH1 mutation was found in 27 patients (6.1%). Among the cytogenetically normal AML patients, the IDH2 mutation was demonstrated in 15.2% (34/223) of patients and IDH1 mutation in 8.9% (20/223) ( Table 1 ). There were three types of R140 mutations, including R140Q (39 of 41, 95.1%), R140L (1 of 41, 2.4%) and R140W (1 of 41, 2.4%), whereas all the R172 mutations were R172K. All patients with IDH2 mutation were heterozygous and retained a wild-type allele.
Correlation of IDH2 and total IDH mutations with clinical features
Comparison of clinical characteristics between patients with and without IDH2 mutations and between patients bearing either IDH1 or IDH2 mutation (hereafter IDH mutation) and those not are shown in Table 1 . Both IDH2 and IDH mutations occurred equally in males and females and distributed evenly among different age groups. For patients bearing IDH2 mutation, the median platelet count at diagnosis was significantly higher (62 vs 42 Â 10 3 per ml, P ¼ 0.046), whereas lactate dehydrogenase level was significantly lower than patients with wild-type IDH2 (564 vs 914 U/l, P ¼ 0.001). There was no significant association between IDH2 mutation and the initial hemoglobin level, white blood cell (WBC) count, and blast percentage. There was also no preference of IDH2 mutation among French-American-British subgroups excluding M3. Similar to IDH2 mutations, combining IDH1 and IDH2 mutations revealed correlation of IDH mutations with higher platelet counts (median, 59 vs 42 Â 10 3 per ml, P ¼ 0.038), as well as lower lactate dehydrogenase levels (median, 731 vs 911 U/l, P ¼ 0.017), but not WBC counts and blast percentages. However, unlike IDH2 mutation, IDH mutation was closely associated with French-American-British M1 subtype (30 of 81 vs 79 of 365, P ¼ 0.006), but inversely associated with M4 (14 of 81 vs 105 of 365, P ¼ 0.037) ( Table 1) .
Association of IDH2 and IDH mutations with cytogenetics and immunophenotypes
Chromosome data were available in 428 patients at diagnosis, including 50 with IDH2 mutation and 378 without this mutation (Table 1) . IDH2 mutation was significantly associated with intermediate-risk cytogenetics (45 of 50 vs 266 of 378, P ¼ 0.002) (defined by Medical Research Council, 34 ) and normal karyotype (34 of 50 vs 189 of 378, P ¼ 0.023). None of the patients with core-binding factor AML (t(8;21) and inv(16)) had IDH2 mutation, neither did patients with t(15;17) (not included in this study). Of note, IDH2 mutation was significantly associated with isolated trisomy 8 (7 of 50 vs 17 of 378, P ¼ 0.014). These karyotypic correlations were even stronger when IDH1 and IDH2 mutations were considered together (Pp0.001, Table 1 ).
Immunophenotyping showed that the IDH2 mutation was inversely associated with the expression of HLA-DR, CD7, CD15, CD34 and CD 56 (P ¼ 0.002, 0.010, 0.003, 0.039 and 0.048, respectively; Supplementary Table 1) . Stronger inverse correlation could also be seen between IDH (combined IDH1/ IDH2) mutations and expression of HLA-DR, CD7, CD15, CD34 and CD56, whereas the trend of negative association of IDH2 mutation with CD14 and CD13 became statistically significant when IDH1 and IDH2 mutations were combined for analysis (Supplementary Table 1 ).
Association of IDH2 and IDH mutations with other molecular abnormalities
To better understand the association between IDH and various other gene mutations in the pathogenesis of adult AML, we performed a complete mutational screening of 14 other genetic alterations in all 446 patients in this study (Table 2) . Among the 54 patients with IDH2 mutation, 43 (79.6%) had at least one concurrent mutation from other 14 genes tested, including 25 with one, 15 with two, and 3 patients with three additional gene mutations (Supplementary Table 2 ). A total of 23 patients (23/43, 53.5%) had concomitant class I mutations, which confer Table 2 ). Patients harboring IDH2 mutation had a significantly lower incidence of WT1 mutation than those with wild-type IDH2 (0 vs 7.7%, P ¼ 0.037).
None of the patients with IDH2 mutation had concomitant IDH1 mutation. The IDH2 mutation showed a trend of positive association with NPM1 mutation (33.3 vs 21.7%, P ¼ 0.083, Table 2 ) but negative association with CEBPA mutation (5.6 vs 15.6%, P ¼ 0.06). These genetic correlations became more obvious when IDH1 and IDH2 mutations were considered as a whole; the mutations were closely associated with NPM1 mutation (40.7 vs 19.2%, Po0.001) but were mutually exclusive with CEBPA and WT1mutations (4.9 vs 16.4%, P ¼ 0.005 and 0 vs 8.2%, P ¼ 0.003, respectively). There was no significant association of IDH mutation with RUNX1, NRAS, FLT3-ITD, FLT3-TKD, MLL-PTD, PTPN11, KRAS, KIT, JAK2 and ASXL1 mutations, whether IDH2 mutation was considered alone or in combination with IDH1 (Table 2 and data not shown).
Comparison of clinical and biological features between AML with IDH2 R140 and R172
We noted some distinctive features in patients with IDH2 R172 mutation as compared with those with IDH2 R140 mutation, including younger age (47 vs 64 years, P ¼ 0.020), a lower initial WBC count (median, 3.58 vs 31.63 Â 10 3 per ml, P ¼ 0.017), and lower lactate dehydrogenase level (median 418 vs 704 U/l, P ¼ 0.013) (Supplementary Table 3 ). The IDH2 R172 mutation was mutually exclusive with NPM1 mutation (0/13 vs 18/41 or 43.9% for IDH2 R140 mutation, P ¼ 0.002), and was less frequently, though not statistically significant, accompanied with FLT3-ITD (1/13 or 7.7 vs 24.4%) (Supplementary Table 4) . On the other hand, a trend of higher incidence of ASXL1 mutations could be seen in IDH2 R172 than in R140-mutated patients (23.1 vs 7.3%; P ¼ 0.143) (Supplementary Table 4 ), but the difference did not reach statistical significance.
Impact of IDH2 mutation on clinical outcome
The impact of IDH2 mutation on clinical outcome was assessed in the cohort of 309 patients receiving intensive chemotherapy. Of the 309 patients, 231 patients (74.8%) achieved a CR. There was no significant difference in CR rate between patients with and without IDH2 mutation (72.2 vs 74.8%, P ¼ 0.690).
Univariate analysis showed that age, karyotype, WBC count, mutations of CEBPA, RUNX1, IDH2 and NPM1/FLT3-ITD were all prognostic factors for OS (Table 3) . With a median follow-up of 50 months (range, 1.3-160 months), patients bearing IDH2, but not IDH1, mutation had better OS than those with wild-type IDH2 (median, not reached vs 20.0 months, P ¼ 0.048) (Figure 1a and Table 3 ). This association became more obvious Table 2 Comparison of concurrent alterations of other genes between AML patients with and without IDH mutation (Figures 1b  and c) . However, there was no difference in disease-free survival or relapse-free survival between the patients with and without IDH2 mutation (data not shown). For younger patients (less than or equal to 60 years), IDH2 mutation still conferred significantly longer OS (median, not reached vs 38.0 months, P ¼ 0.043) (Figure 1d and Supplementary Table 5 ). In multivariate analysis using well studied prognostic factors such as age, karyotype, WBC count and mutation status of NPM1 þ / FLT3-ITD À , CEBPA double mutant WT1 and RUNX1 mutations as covariates, IDH2 mutation was an independent favorable prognostic factor (hazard ratio 0.311, 95% confidence interval 0.142 to 0.680, P ¼ 0.003) ( Table 4) .
When IDH1 and IDH2 mutations were considered together, the CR rate after induction chemotherapy was similar between patients with and without the mutation (77.6 vs 73.8%, P ¼ 0.619). In univariate analysis, patients bearing IDH mutations as a whole had a trend of better OS than wild-type IDH (median, 69.0 months vs 22.0 months, P ¼ 0.086) (Table 3) . Again, the trend was more obvious in the subgroup of patients with normal karyotype (median, not reached vs 58.0 months, P ¼ 0.029) or intermediate cytogenetics (median, 69.0 months vs 18.0 months, P ¼ 0.035) (data not shown). In multivariate analysis, like IDH2 mutation, IDH mutation remained an independent favorable prognostic factor (hazard ratio: 0.417, 95% confidence interval: 0.238-0.731, P ¼ 0.002; footnote of Age older than 50 years relative to age 50 years or younger. c WBC greater than 50 Â 10 3 per ml versus less than 50 Â 10 3 per ml. When using IDH (IDH1/IDH2) mutation instead of IDH2 mutation as a covariate, the hazard ratio for overall survival (OS) was 0.417, with 95% confidence interval: 0.238-0.731 and a P-value of 0.002. not FLT3-ITD (median OS, 12 months vs 35 months vs not reached, Po0.0001, Figure 2a) . Similar finding could be seen when IDH2 mutations were replaced by IDH mutations in the analyses (Figure 2b ). Because NPM1 and IDH mutations were often coexistent, the better prognosis from IDH mutations in these sub-group analyses might be because of the presence of NPM1 mutations. To exclude this possibility, we performed the same analyses with the exclusion of the patients with NPM1 mutation. Patients with NPM1 À /IDH2 À /FLT3-ITD þ genotype still had worse OS compared with those with NPM1 À /IDH2 þ / FLT3-ITD À or other genotypes (median OS, 12 months vs not reached vs 25 months; Po0.001) (Supplementary Figure 1) . When the prognostic significance of IDH2/IDH mutations was analyzed either in the subgroup of low molecular risk (NPM1 þ / FLT3-ITD À ) or high molecular risk genotypes (other than NPM1 þ /FLT3-ITD À ), no significant survival difference was noted whether IDH2/IDH was mutated or not, though there was a trend of longer survival in the patients with IDH2 or IDH mutation than those without in the subgroup with high-risk genotype (not reached vs 20 months, P ¼ 0.140, and 69 vs 20 months, P ¼ 0.187, respectively, Supplementary Figure 2) .
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Sequential studies of IDH2 mutations
The IDH2 mutation was studied in 315 samples obtained at diagnosis and disease relapse from 121 patients, including eight patients with and 113 patients without IDH2 mutation at diagnosis. The results of sequential studies of the eight patients bearing IDH2 mutation at diagnosis are shown in Supplementary Table 6 . The original IDH2 mutation remained in all samples obtained at relapse with the exception of patient 13 (Supplementary Table 6 ) who had extramedullary relapse when the bone marrow was in morphological remission. In patient 5, the IDH2 mutation could only be detected by TA cloning, but not by direct sequencing, at relapses one and three, probably because of low percentages of leukemic blasts at these two time points. In all 113 patients without IDH2 mutation at diagnosis, none acquired this mutation during disease relapse (data not shown). Overall, IDH2 mutation seemed to be stable during disease evolution.
Discussion
In this study, we characterized the clinical and biological features of adult AML with IDH2 mutations in a large cohort of patients and integrated IDH1 and IDH2 mutations together. One interesting observation in our study is the 'paradox' in the characteristics between AML with IDH1 and IDH2 mutations. On the one hand, patients with IDH1 and IDH2 mutations showed some similar clinical characteristics; on the other hand, IDH2, but not IDH1, mutations appear to confer a good outcome in AML patients. Both IDH1 and IDH2 enzymes can convert isocitrate to a-ketoglutarate and generate nicotinamide adenine dinucleotide phosphate (NADPH), both of which are important in regulation of cellular redox state and protection from oxidative damages. 11 Mutations of both genes result in production of 2-HG and decrease of NADPH, metabolites related to redox homeostasis. 1, 8 Therefore, the similarities of some clinical and biological features of these two mutations can be explained by disruption of cellular redox homeostasis. However, there are important differences between IDH1 and IDH2. The former resides in cytosol and peroxisome, whereas the latter is located in mitochondria. Although a-ketoglutarate can shuttle between mitochondria and cytosol to compensate for loss from either IDH1 or IDH2 mutation, NADPH cannot permeate through mitochondrial inner membrane. 11 Therefore, IDH2 but not IDH1 mutation is directly related to insult of mitochondria-specific oxidative stress generated from respiratory electron transport chain. In addition, IDH2 mutation may change the mitochondrial metabolite pools with unbalanced interconvertion between nicotinamide adenine dinucleotide and NADPH, thus interfere with IDH3-mediated aerobic metabolism of the tricyclic acid cycle. 35 In addition, IDH1 uniquely resides in peroxisome and provides NADPH for cholesterol synthesis and lipid metabolism. 36 In light of the impact of reactive oxygen species, and glucose and lipid metabolism on cancer progression and susceptibility to drug toxicity, [37] [38] [39] it is quite possible that IDH1 and IDH2 mutations exert different effects on tumorigenesis and treatment response.
In this study, IDH2 but not IDH1 mutation was an independent favorable prognostic factor in all non-M3 or cytogenetically normal AML. Similarly, Ward et al. showed a trend of better survival (P ¼ 0.08) in patients with IDH2 mutation, 8 and Abbas et al. demonstrated a longer survival in IDH2-mutated patients than IDH2-wild patients with a P-value of 0.047 ( Figure 1a of the paper) . 7 On the other hand, Thol et al. did not find prognostic implication of IDH2 mutation. 15 More bewilderingly, some studies revealed negative impact on prognosis of IDH2 mutation in subgroup analysis. 9, 17, 18 Marcucci et al. reported lower CR rate in the cytogenetically normal AML patients with IDH2 R172 mutation, but no impact of total IDH2 (R140 or R172) mutations on OS was seen. 9 In another study, only in low molecular risk sub-group (NPM1 þ / FLT3-ITD À ) did significantly shorter relapse-free survival and OS in those with IDH mutation appear. 17 The OS difference was weakened to become insignificant when IDH2 mutation was considered alone. 17 Boissel et al. found that cytogenetically normal AML patients with IDH2 R172 mutation was associated with higher risk of relapse and shorter OS, but R140 mutation was excluded from analysis. 18 Overall, the significance of IDH2 mutation on AML patients' prognosis still remains controversial (Supplementary Table 7 ). This is not surprising as the component of population and the type of mutation analyzed in these studies were quite heterogeneous. Further large-scale studies or metaanalysis is needed to reach a more convincing conclusion regarding this point. Whether there is a racial factor underlying these discrepancies awaits further investigation.
Although it seems counter-intuitive to see differences between AML bearing IDH2 R140 and R172 mutations, we are not the only group reporting this interesting observation. Marcucci et al. 9 has found unique signatures in both mRNA and microRNA arrays in leukemia cells carrying IDH2 R172K mutation, but in that study IDH2 R172 mutation was mutually exclusive with all other prognostically relevant mutations, and tended to occur in older patients, different from ours. IDH2 R172 aligns with IDH1 R132 by structure and both are important in IDH enzyme activities by binding to â-carboxyl group of isocitrate.
11 IDH2 R140 was hypothesized to function analogously with IDH2 R172 on the basis of proximity of these two residues to isocitrate substrate, however, it has not been confirmed that mutations at these two sites behave identically in vivo. It is possible that the extent of compromise in enzyme activities by these two mutations is not equal, thus leading to different degrees of NADPH reduction and 2-HG production and redox deregulation. Direct measurement of 2-HG and oxidative stress in cells bearing these two mutations is necessary to test this hypothesis. Taken together, these findings indicated some distinct pathological roles among mutations of IDH1 R132, IDH2 R140 and IDH2 R172 in leukemia cells, although the physiological functions of IDH1 and IDH2 are similar.
We also found a synergistic effect on poor clinical outcome from wild-type IDH2 and FLT3-ITD (IDH2 À /FLT3-ITD þ ) (Figure 2a ). Of our patients bearing this genotype o20% were alive at the time of this study, compared with over 70% in the patients with IDH2
þ /FLT3-ITD À genotype (Figure 2a) . The favorable effect of mutated IDH2 on survival did not seem to be related to coexistent NPM1 mutation, as the prognostic significance of IDH2 À /FLT3-ITD þ remained even though patients with NPM1 mutation were excluded. This is the first report of sequential study of IDH2 mutation at both diagnosis and relapse in AML patients throughout the clinical course. We found that, like IDH1 mutation, 14, 19 IDH2 mutation seemed quite stable.
In conclusion, we have performed comprehensive analyses in the clinical and biological features of IDH2 mutations and demonstrated that this mutation was an independent favorable prognostic factor. There seem to be both similarities and distinctions among AML with mutations in IDH1 R132, IDH2 R140 and IDH2 R172 in vivo. FLT3-ITD and wild-type IDH2 exerted a synergistic negative effect on survival in AML patients. IDH2 mutations were quite stable during disease progression and may serve as a potential marker for minimal residual disease monitoring.
